CClinicalTrials.gg
RecruitingNCT06004349Updated Jul 8, 2026

Autoimmune and Autoinflammatory Genetics Study

An observational study in VEXAS Syndome, Autoinflammatory Disease and Autoimmune Disease, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 1 Month and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by NYU Langone Health · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
1 Month and older
Sex
All
01

Study summary

This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.

Read the detailed description

This is a single-site protocol designed to test the hypothesis that genetic factors contribute to susceptibility to human disorders of inflammation, and the hypothesis that identifying such genetic susceptibility factors will contribute to our understanding of the immunologic mechanisms of these diseases.

There are 3 main objectives:

Primary Objective: To discover the genetic basis of human disorders of inflammation or autoinflammatory diseases.

Secondary Objective: To enumerate immunologic features and genotype-phenotype associations in specific inflammatory diseases, such as VEXAS syndrome.

Tertiary/Exploratory Objective: To describe the clinical features of poorly characterized or newly defined disorders of inflammation, such as VEXAS syndrome, through the retrospective chart review of standard medical practice follow up

02

Conditions studied

  • VEXAS Syndome
  • Autoinflammatory Disease
  • Autoimmune Disease
  • Rheumatic Disease

Keywords

  • VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic)
03

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

There are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases (i.e., Probands), family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. Subjects will be recruited regardless of gender, demographic group, or general health status. Probands and family members must be more than one month of age at time of enrollment; healthy controls must be over 5 years old.

Inclusion criteria

In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures (which at the very least includes providing a mail-in blood or saliva sample for genetic analysis);
  • Regardless of sex assigned at birth, at least one month of age;
  • A medical history that, in the expert opinion of the PI and study team, is consistent with the possibility of autoinflammatory disease or known diagnosis of an autoinflammatory disease, such as VEXAS syndrome; and
  • Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  • Regardless of sex assigned at birth, at least one month of age;
  • Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
  • Likelihood, in the expert opinion of the PI and study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative's possible autoinflammatory condition; and
  • Ability of the subject, parents (in the case of children), to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures for healthy volunteers;
  • Regardless of sex assigned at birth, at least five years old, and not pregnant (by history of a missed menstrual period);
  • Likelihood, in the expert opinion of the PI that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
  • Ability of the subject to understand and the willingness to sign a written informed consent document by a capacity assessment provided by the PI and study team.

Exclusion criteria

Exclusion Criteria:

For any of the three categories of subjects, an individual will be excluded from participation in this study for the following reasons:

Probands: an individual will not be enrolled as a proband if the study team has a low suspicion of having an autoinflammatory disease or a genetic cause for an autoinflammatory disease.

Family Members: an individual will not be enrolled as a family member if the study team believes they may have an autoinflammatory disease, in which case, they will be enrolled as a proband.

Healthy controls: an individual will not be enrolled as a healthy control if they have an autoinflammatory disease, or any condition that may mimic an autoinflammatory disease, such as hematologic malignancy, rheumatologic disease.

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with known or suspected autoinflammatory diseases

    Participants with known or suspected autoinflammatory diseases (i.e., Probands)

  • Family member

    Family member, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease.

  • Healthy control
05

What researchers measure

Primary outcomes

  1. Number of newly discovered rare, high penetrance germline variants that cause human inflammatory disease

    Time frame: Study End (Up to Year 5)

  2. Number of newly discovered structural genomic variants that cause human inflammatory disease

    Time frame: Study End (Up to Year 5)

  3. Number of newly discovered common, low penetrance germline variants that confer susceptibility to human inflammatory disease

    Time frame: Study End (Up to Year 5)

  4. Number of newly discovered somatic mutations that give rise to human inflammatory disease

    Time frame: Study End (Up to Year 5)

06

Study locations

2 of 2 sites recruiting
  • NYC H+H/Bellevue
    New York, New York 10016, United States
    Recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
07

References and documents

Publications

  • Beck DB, Bodian DL, Shah V, Mirshahi UL, Kim J, Ding Y, Magaziner SJ, Strande NT, Cantor A, Haley JS, Cook A, Hill W, Schwartz AL, Grayson PC, Ferrada MA, Kastner DL, Carey DJ, Stewart DR. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population. JAMA. 2023 Jan 24;329(4):318-324. doi: 10.1001/jama.2022.24836. PubMed 36692560 ↗
  • Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, Kumar DBU, Wilson L, Goodspeed W, Topilow JS, Paik JJ, Poulter JA, Kermani TA, Koster MJ, Warrington KJ, Cargo C, Tattersall RS, Duncan CJA, Cantor A, Hoffmann P, Payne EM, Bonnekoh H, Krause K, Cowen EW, Calvo KR, Patel BA, Ombrello AK, Kastner DL, Young NS, Werner A, Grayson PC, Beck DB. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022 Sep 29;140(13):1496-1506. doi: 10.1182/blood.2022016985. PubMed 35793467 ↗

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request with investigators whose proposed use of the data has been approved by the PI, Dr. David Beck, beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: BeckClinic@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Sap

08

Registry details

Key details

Study ID
NCT06004349
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Apr 15, 2022
Primary completion
Apr 5, 2032 (estimated)
Completion
Apr 5, 2032 (estimated)
Last update
Jul 8, 2026

Study contacts

David Beck, MD, PhD
Contact
BeckClinic@nyulangone.org
646-501-7400
Mei-Kay Wong, MS, MPH, CGC, CPH
Contact
BeckClinic@nyulangone.org
212-263-0350
David Beck, MD, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion